Literature DB >> 8977368

Inhibitors of the renin-angiotensin system in established cardiac failure.

K Chatterjee1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8977368      PMCID: PMC484494          DOI: 10.1136/hrt.76.3_suppl_3.83

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  24 in total

1.  Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart.

Authors:  H Urata; A Kinoshita; K S Misono; F M Bumpus; A Husain
Journal:  J Biol Chem       Date:  1990-12-25       Impact factor: 5.157

2.  Inhibition of angiotensin converting enzyme by ramipril in serum and tissue of man.

Authors:  A Erman; J Winkler; B Chen-Gal; M Rabinov; A Zelykovski; S Tadjer; J Shmueli; E Levi; A Akbary; J B Rosenfeld
Journal:  J Hypertens       Date:  1991-11       Impact factor: 4.844

3.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.

Authors:  J N Cohn; G Johnson; S Ziesche; F Cobb; G Francis; F Tristani; R Smith; W B Dunkman; H Loeb; M Wong
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

4.  Application of cine nuclear magnetic resonance imaging for sequential evaluation of response to angiotensin-converting enzyme inhibitor therapy in dilated cardiomyopathy.

Authors:  N E Doherty; K C Seelos; J Suzuki; G R Caputo; M O'Sullivan; S M Sobol; P Cavero; K Chatterjee; W W Parmley; C B Higgins
Journal:  J Am Coll Cardiol       Date:  1992-05       Impact factor: 24.094

5.  Myocardial blood flow response to pacing tachycardia and to dipyridamole infusion in patients with dilated cardiomyopathy without overt heart failure. A quantitative assessment by positron emission tomography.

Authors:  D Neglia; O Parodi; M Gallopin; G Sambuceti; A Giorgetti; L Pratali; P Salvadori; C Michelassi; M Lunardi; G Pelosi
Journal:  Circulation       Date:  1995-08-15       Impact factor: 29.690

6.  Effect of selective angiotensin II receptor antagonism and angiotensin converting enzyme inhibition on the coronary vasculature in vivo. Intravascular two-dimensional and Doppler ultrasound studies.

Authors:  K Sudhir; J S MacGregor; M Gupta; S D Barbant; R Redberg; P G Yock; K Chatterjee
Journal:  Circulation       Date:  1993-03       Impact factor: 29.690

7.  Coronary flow reserve in patients with dilated cardiomyopathy.

Authors:  T Inoue; Y Sakai; S Morooka; T Hayashi; K Takayanagi; T Yamanaka; H Kakoi; Y Takabatake
Journal:  Am Heart J       Date:  1993-01       Impact factor: 4.749

8.  Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group.

Authors:  I Crozier; H Ikram; N Awan; J Cleland; N Stephen; K Dickstein; M Frey; J Young; G Klinger; L Makris
Journal:  Circulation       Date:  1995-02-01       Impact factor: 29.690

9.  Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure.

Authors:  K Dickstein; P Chang; R Willenheimer; S Haunsø; J Remes; C Hall; J Kjekshus
Journal:  J Am Coll Cardiol       Date:  1995-08       Impact factor: 24.094

10.  Decreased coronary sinus oxygen content: a predictor of adverse prognosis in patients with severe congestive heart failure.

Authors:  M White; J L Rouleau; T D Ruddy; T De Marco; D Moher; K Chatterjee
Journal:  J Am Coll Cardiol       Date:  1991-12       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.